Literature DB >> 29548365

Multiparametric (mp) MRI of prostate cancer.

Virendra Kumar1, Girdhar S Bora2, Rajeev Kumar3, Naranamangalam R Jagannathan4.   

Abstract

Prostate cancer (PCa) is one of the most prevalent cancers in men. A large number of men are detected with PCa; however, the clinical behavior ranges from low-grade indolent tumors that never develop into a clinically significant disease to aggressive, invasive tumors that may rapidly progress to metastatic disease. The challenges in clinical management of PCa are at levels of screening, diagnosis, treatment, and follow-up after treatment. Magnetic resonance imaging (MRI) methods have shown a potential role in detection, localization, staging, assessment of aggressiveness, targeting biopsies, etc. in PCa patients. Multiparametric MRI (mpMRI) is emerging as a better option compared to the individual imaging methods used in the evaluation of PCa. There are attempts to improve the reproducibility and reliability of mpMRI by using an objective scoring system proposed in the prostate imaging reporting and data system (PIRADS) for standardized reporting. Prebiopsy mpMRI may be used to detect PCa in men with elevated prostate-specific antigen or abnormal digital rectal examination and to enable targeted biopsies. mpMRI can also be used to decide on clinical management of patients, for example active surveillance, and may help in detecting only the pathology that requires detection. It can potentially not only guide patient selection for initial and repeat biopsy but also reduce false-negative biopsies. This review presents a description of the MR methods most commonly applied for investigations of prostate. The anatomical, functional and metabolic parameters obtained from these MR methods are discussed with regard to their physical basis and their contribution to mpMRI investigations of PCa.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffusion weighted imaging; Dynamic contrast enhanced MRI; Magnetic resonance spectroscopy; Multiparametric MRI; Prostate cancer

Mesh:

Year:  2018        PMID: 29548365     DOI: 10.1016/j.pnmrs.2018.01.001

Source DB:  PubMed          Journal:  Prog Nucl Magn Reson Spectrosc        ISSN: 0079-6565            Impact factor:   9.795


  10 in total

1.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

2.  A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions.

Authors:  Ying Hou; Mei-Ling Bao; Chen-Jiang Wu; Jing Zhang; Yu-Dong Zhang; Hai-Bin Shi
Journal:  Abdom Radiol (NY)       Date:  2020-08-01

3.  Biophysical review's 'meet the editors series'-a profile of Naranamangalam R. Jagannathan.

Authors:  Naranamangalam R Jagannathan
Journal:  Biophys Rev       Date:  2020-05-27

4.  Assessment of elastographic Q-analysis score combined with Prostate Imaging-Reporting and Data System (PI-RADS) based on transrectal ultrasound (TRUS)/multi-parameter magnetic resonance imaging (MP-MRI) fusion-guided biopsy in differentiating benign and malignant prostate.

Authors:  Hongtian Tian; Zhimin Ding; Huaiyu Wu; Keen Yang; Di Song; Jinfeng Xu; Fajin Dong
Journal:  Quant Imaging Med Surg       Date:  2022-07

5.  A novel method for pain control: infiltration free local anesthesia technique (INFLATE) for transrectal prostatic biopsy using transcutaneous electrical nerve stimulation (TENS).

Authors:  Mustafa Suat Bolat; Onder Cinar; Ramazan Asci; Recep Buyukalpelli
Journal:  Int Urol Nephrol       Date:  2019-09-06       Impact factor: 2.370

Review 6.  MRI-targeted prostate biopsy: the next step forward!

Authors:  Emanuel Darius Cata; Iulia Andras; Teodora Telecan; Attila Tamas-Szora; Radu-Tudor Coman; Dan-Vasile Stanca; Ioan Coman; Nicolae Crisan
Journal:  Med Pharm Rep       Date:  2021-04-29

7.  PEG-coated and Gd-loaded fluorescent silica nanoparticles for targeted prostate cancer magnetic resonance imaging and fluorescence imaging.

Authors:  Wei Jiang; Huiying Fang; Fengqiu Liu; Xue Zhou; Hongyun Zhao; Xiaojing He; Dajing Guo
Journal:  Int J Nanomedicine       Date:  2019-07-23

Review 8.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 9.  Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer.

Authors:  R Ravikanth Reddy; Naranamangalam R Jagannathan
Journal:  Indian J Urol       Date:  2022-04-01

10.  Quantib Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study.

Authors:  Eliodoro Faiella; Daniele Vertulli; Francesco Esperto; Ermanno Cordelli; Paolo Soda; Rosa Maria Muraca; Lorenzo Paolo Moramarco; Rosario Francesco Grasso; Bruno Beomonte Zobel; Domiziana Santucci
Journal:  Tomography       Date:  2022-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.